FamiCord AG
FamiCord AG
Your view on VTIAF
Overview
What the company does, where it operates, and who runs it.
About FamiCord AG
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jakub Julian Baran
- Headquarters
- Deutscher Platz 5a, Leipzig, DE
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jakub Julian Baran
- Headquarters
- Deutscher Platz 5a, Leipzig, DE
VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T.
In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates.
VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for FamiCord AG, and the rating behind it. VTIAF last traded at $6.38; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for FamiCord AG. Starting points for FamiCord AG: EPS -$0.44, beta 0.72 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for FamiCord AG. FamiCord AG does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for FamiCord AG. Trailing twelve-month EPS for FamiCord AG stands at -$0.44. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for FamiCord AG. FamiCord AG has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
FamiCord AG valued side by side against its closest peers. FamiCord AG is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold FamiCord AG, and how their positions are changing. At a $111.1M market value, institutional positions materially move FamiCord AG's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by FamiCord AG executives and directors. Shares of FamiCord AG have traded between $4.57 and $7.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming FamiCord AG. FamiCord AG is a $111.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming FamiCord AG. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for FamiCord AG. Coverage tracks FamiCord AG within Biotechnology (Healthcare). Press releases and market coverage, newest first.